Status:
COMPLETED
Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia
Lead Sponsor:
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Collaborating Sponsors:
Queen's University
Northern Ontario School of Medicine
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
PHASE2
Brief Summary
The objective of the study is to determine whether Panax Ginseng with multiple interactions with key components of brain signaling pathway, can augment the effects of antipsychotics in Schizophrenia. ...
Detailed Description
Schizophrenia is a serious mental disorder affecting individuals in multiple ways: behavior control, emotional and information processing and the functional levels conforming to societal norms. Despit...
Eligibility Criteria
Inclusion
- Male or female
- age 18-65 years
- DSM-IV diagnosis of Schizophrenia
- SANS score greater than 30
Exclusion
- Current (past 12 months) substance use disorder
- Except nicotine dependence
- Major medical disorders : hematological disorder
- Chronic active hepatitis, acute hepatitis, cirrhosis of liver, AIDS
- Pregnancy and breast-feeding
- Neurological disorders including epilepsy
- traumatic brain injury
- HAM-D score greater than 24
Key Trial Info
Start Date :
December 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00401089
Start Date
December 1 2002
End Date
October 1 2007
Last Update
December 12 2012
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen's University
Kingston, Ontario, Canada
2
Regional Mental Health Care London
St. Thomas, Ontario, Canada, N5P 3V9
3
Northern Ontario Medical School
Thunder Bay, Ontario, Canada
4
Northwick Park Hospital
Harrow, Middlesex, United Kingdom, HA13UJ